Department of Biochemistry and Molecular Biology, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND 58202, USA.
Trends Pharmacol Sci. 2013 Sep;34(9):489-96. doi: 10.1016/j.tips.2013.07.005. Epub 2013 Aug 20.
The dopamine (DA) transporter (DAT) controls the spatial and temporal dynamics of DA neurotransmission by driving reuptake of extracellular transmitter into presynaptic neurons. Many diseases such as depression, bipolar disorder, Parkinson's disease (PD), and attention deficit hyperactivity disorder (ADHD) are associated with abnormal DA levels, implicating DAT as a factor in their etiology. Medications used to treat these disorders and many addictive drugs target DAT and enhance dopaminergic signaling by suppressing transmitter reuptake. We now understand that the transport and binding properties of DAT are regulated by complex and overlapping mechanisms that provide neurons with the ability to modulate DA clearance in response to physiological demands. These processes are controlled by endogenous signaling pathways and affected by exogenous transporter ligands, demonstrating their importance for normal neurotransmission, drug abuse, and disease treatments. Increasing evidence supports the disruption of these mechanisms in DA disorders, implicating dysregulation of transport in disease etiologies and suggesting these processes as potential points for therapeutic manipulation of DA availability.
多巴胺(DA)转运体(DAT)通过将细胞外递质再摄取到突触前神经元中来控制 DA 神经传递的空间和时间动态。许多疾病,如抑郁症、双相情感障碍、帕金森病(PD)和注意缺陷多动障碍(ADHD),都与异常的 DA 水平有关,这表明 DAT 是其发病机制的一个因素。用于治疗这些疾病的药物和许多成瘾性药物都以 DAT 为靶点,并通过抑制递质再摄取来增强多巴胺能信号。我们现在知道,DAT 的转运和结合特性受到复杂且重叠的机制的调节,这些机制为神经元提供了根据生理需求调节 DA 清除的能力。这些过程受内源性信号通路的控制,并受外源性转运体配体的影响,这表明它们对正常神经传递、药物滥用和疾病治疗的重要性。越来越多的证据支持在 DA 疾病中这些机制的破坏,这表明在疾病发病机制中转运的失调,并暗示这些过程可能是治疗性操纵 DA 可用性的潜在靶点。